Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial.

ABSTRACT:

Purpose

Everolimus decreases tumor volume of renal angiomyolipomas in patients with tuberous sclerosis. No prospective data are available regarding the effect of everolimus on the growth kinetics in patients with sporadic angiomyolipomas. We sought to determine the safety and efficacy of everolimus in the volumetric reduction of sporadic angiomyolipomas.

Materials and methods

This multi-institutional, prospective, phase II trial, enrolled patients with 3 cm or larger sporadic angiomyolipomas who were candidates for surgical resection or percutaneous angioembolization. Patients received 10 mg everolimus daily for 4 planned 28-day cycles. Response was defined as a 25% or greater volumetric reduction of patient angiomyolipoma. Baseline, 4, 6 and 12-month volumetric analyses wer

SUBMITTER: Geynisman DM 

PROVIDER: S-EPMC7695484 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature